08:00 , Nov 4, 2002 |  BC Week In Review  |  Company News

Aeson, Hollis-Eden deal

HEPH said it would not exercise its option under a 2000 deal to purchase the 75% of Aeson it does not already own (see BioCentury, Oct. 16, 2000). HEPH said it will focus its financial...
07:00 , Oct 16, 2000 |  BC Week In Review  |  Company News

Aeson, Hollis-Eden deal

HEPH acquired an exclusive worldwide sublicense to three Aeson patents covering adrenal steroids. HEPH also acquired a 21 percent equity stake in Aeson in exchange for $2 million in cash and 208,681 shares of HEPH...
08:00 , Mar 16, 1998 |  BC Week In Review  |  Clinical News

Fluasterone synthetic steroid data

Aeson said results of its Swiss Phase I trial with fluasterone in healthy volunteers showed that the product is safe at high doses and not metabolized to testosterone or estrogen in men or women. A...
08:00 , Dec 18, 1995 |  BC Week In Review  |  Company News

Aeson, Research Corp. Technologies, Temple University deal

Research Corp. Technologies (RCT) formed Aeson Therapeutics to develop fluasterone, a synthetic version of dehydrepi-androsterone (DHEA), to prevent breast cancer, and as a treatment for lupus erythematosus and Type II diabetes. Aeson, which will receive...